Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with Merck's (MRK) immuno-oncology agent Keytruda significantly improved ...

Gilead Sciences, Inc. today announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy ® in combination with Merck’ s anti-PD-1 therapy KEYTRUDA ...

As part of the collaboration, Merck will sponsor a global Phase 3 clinical trial of Trodelvy in combination with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC.

Gilead's Trop-2 targeting antibody-drug conjugate Trodelvy (sacituzumab govitecan) will be paired with Merck's PD-1 inhibitor Keytruda (pembrolizumab) in a new phase 3 trial in previously ...

Immunomedics has collaborated with the Dana-Farber Cancer Institute to conduct two phase II studies to evaluate the safety and efficacy of combining Trodelvy with Merck’s MRK anti-programmed ...